The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
Open accessAbstract
UNLABELLED: Schizophrenia is a chronic and disabling brain disease characterized by psychotic episodes with unknown etiology. It is suggested that neuroinflammation plays a role in the pathophysiology of schizophrenia. Neuroinflammation is characterized by the activation of microglia cells, which show an increase in the expression of the peripheral benzodiazepine receptor. The isoquinoline (R)-N-(11)C-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide ((11)C-(R)-PK11195) is a peripheral benzodiazepine receptor ligand that can be used for the imaging of activated microglia cells, and thus neuroinflammation, with PET. We hypothesized that neuroinflammation would be more profound in schizophrenic patients during psychosis, and it was therefore investigated whether neuroinflammation was present in patients within the schizophrenia spectrum who were in a psychotic phase. METHODS: Seven patients within the schizophrenia spectrum who were recovering from psychosis were included. Recovering psychosis was defined by a score of 5 or more on 1 item of the positive scale of the positive and negative symptoms scale (PANSS) or a score of 4 on 2 items. The patients were compared with 8 age-matched healthy volunteers. Dynamic 60-min PET scans were acquired after the injection of (11)C-(R)-PK11195. All subjects underwent T1- and T2-weighted MRI, and the scans were visually examined for abnormalities and used for anatomic coregistration in data analysis. The PET data were analyzed with a 2-tissue-compartment model to calculate the binding potential, using the metabolite-corrected plasma curve as input. RESULTS: A significantly higher binding potential of (11)C-(R)-PK11195, indicative of neuroinflammation, was found in the hippocampus of schizophrenic patients than in healthy volunteers (2.07 +/- 0.42 vs. 1.37 +/- 0.30; P = 0.004). A nonsignificant 30% higher (11)C-(R)-PK11195 binding potential was found in the whole-brain gray matter of schizophrenic patients. The MR images did not reveal any visual abnormalities. CONCLUSION: The present study suggests that focal neuroinflammation may play an important role in schizophrenia during psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · cited 1×
“In healthy brain tissue, microglia cells have a ramified morphology, characterized by long processes that continuously survey the microenvironment (2).”
BackgroundMeta-analysis of regional brain volumes in schizophrenia
Wright, I. C., Rabe-Hesketh, S., Woodruff, P. W. R., David, A. S., Murray, R. M., & Bullmore, E. T. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.16 · Cited by 1,662
Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., Suckling, J., Phillips, L. J., Yung, A. R., Bullmore, E. T., Brewer, W., Soulsby, B., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12323-9 · Cited by 1,310
Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.-G., & Bogerts, B. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.013 · Cited by 791
Harrison, P. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1761-y · Cited by 693
S100B in brain damage and neurodegeneration
Rothermundt, M., Peters, M., Prehn, J. H. M., & Arolt, V. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10303 · Cited by 609
van Berckel, B. N., Bossong, M. G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., Luurtsema, G., Windhorst, A. D., Cahn, W., Lammertsma, A. A., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.025 · Cited by 582
Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair
Chen, M.-K., & Guilarte, T. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.12.004 · Cited by 506
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Increase in HLA-DR Immunoreactive Microglia in Frontal and Temporal Cortex of Chronic Schizophrenics
Radewicz, K., Garey, L. J., Gentleman, S. M., & Reynolds, R. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.2.137 · Cited by 342
Evidence for activation of microglia in patients with psychiatric illnesses
Bayer, T. A., Buslei, R., Havas, L., & Falkai, P. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00545-5 · Cited by 323
Banati, R. B., Myers, R., & Kreutzberg, G. W. (1997) · Journal of Neurocytology · doi:10.1023/a:1018567510105 · Cited by 297
AKHONDZADEH, S., TABATABAEE, M., AMINI, H., AHMADIABHARI, S., ABBASI, S., & BEHNAM, B. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.016 · Cited by 289
Drug-induced stimulation and suppression of action monitoring in healthy volunteers
de Bruijn, E. R. A., Hulstijn, W., Verkes, R. J., Ruigt, G. S. F., & Sabbe, B. G. C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1915-6 · Cited by 282
Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization
Steiner, J., Mawrin, C., Ziegeler, A., Bielau, H., Ullrich, O., Bernstein, H.-G., & Bogerts, B. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0090-8 · Cited by 229
Kuhlmann, A. C., & Guilarte, T. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741694.x · Cited by 215
Arnold, S. E., Trojanowski, J. Q., Gur, R. E., Blackwell, P., Han, L.-Y., & Choi, C. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.225 · Cited by 199
Hippocampal Neuron Number in Schizophrenia: A Stereological Study
Heckers, S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810350042006 · Cited by 187
Raghavendra Rao, V. L., Dogan, A., Bowen, K. K., & Dempsey, R. J. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7269 · Cited by 185
Translocator protein (18 kDa) TSPO: An emerging therapeutic target in neurotrauma
Papadopoulos, V., & Lecanu, L. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.04.016 · Cited by 180
Risperidone significantly inhibits interferon-γ-induced microglial activation in vitro
Kato, T., Monji, A., Hashioka, S., & Kanba, S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.019 · Cited by 174
Wilms, H., Claasen, J.-H., Röhl, C., Sievers, J., Deuschl, G., & Lucius, R. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.07.002 · Cited by 173
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146
Müller, N., & Schwarz, M. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-2012-3 · Cited by 140
Wierzba‐Bobrowicz, T., Lewandowska, E., Lechowicz, W., Stępień, T., & Pasennik, E. (2005) · PubMed · Cited by 136
Steiner, J. H., Bielau, H., Hg, B., Bogerts, B., & Wunderlich, M. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.093427 · Cited by 122
Doorduin, J., de Vries, E. F. J., Dierckx, R. A. J. O., & Klein, H. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786549443 · Cited by 115
Self-citationIs damage in central nervous system due to inflammation?
Chavarría, A., & Alcocer-Varela, J. C. (2003) · Autoimmunity Reviews · doi:10.1016/j.autrev.2003.09.006 · Cited by 113
Estimated Neuronal Populations and Volumes of the Hippocampus and Its Subfields in Schizophrenia
Walker, M. A., Highley, J. R., Esiri, M. M., McDonald, B., Roberts, H. C., Evans, S. P., & Crow, T. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.821 · Cited by 111
Itzhak, Y., Baker, L., & Norenberg, M. D. (1993) · Glia · doi:10.1002/glia.440090306 · Cited by 105
Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia
Falke, E., Han, L.-Y., & Arnold, S. E. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00104-9 · Cited by 77
Hou, Y., Wu, C. F., Yang, J., He, X., Bi, X. L., Yu, L., & Guo, T. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.05.006 · Cited by 72
Sarnowska, A., Beręsewicz, M., Zabłocka, B., & Domanska-Janik, K. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.01.024 · Cited by 66
Lau, J. Y. F., & Pine, D. S. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0788-1 · Cited by 50
Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics
Kurumaji, A., WAKAI, T., & Toru, M. (1997) · Journal of Neural Transmission · doi:10.1007/bf01294737 · Cited by 45
Itzhak, Y., & Norenberg, M. D. (1994) · Brain Research · doi:10.1016/0006-8993(94)91311-0 · Cited by 13
Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia
Kane, J. M., Zhao, J., & Panagides, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.026 · Cited by 5
Cited by
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
Maternal immune activation and abnormal brain development across CNS disorders
Knuesel, I., Chicha, L., Britschgi, M., Schobel, S. A., Bodmer, M., Hellings, J. A., Toovey, S., & Prinssen, E. P. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.187 · Cited by 880
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
Self-citationNeuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
“Several additional experimental and human studies examined in more detail the mechanisms underlying the pathophysiology of increased oxidative stress in psychiatric disorders [206-262].”
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648
Metadata
- Authors
- Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R. A., & Klein, H. C.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2009-10-16
- Volume
- 50
- Issue
- 11
- Pages
- 1801-1807
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2108598556
- Cited by
- 559
- References
- 39
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.